Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Toll-like receptors
Research
George Church launches startup aimed at safer gene therapy
A Harvard team led by George Church founded Ally Therapeutics to develop a way to "cloak" viral vectors from immune surveillance.
Angus Liu
Feb 10, 2021 2:00pm
Stopping cancer before it develops
Jun 5, 2019 2:00pm
Idera’s TLR9-Yervoy combo works in PD-1-refractory melanoma
Dec 14, 2018 10:48am
Targeting Alzheimer’s with a soluble toll-like receptor
Aug 29, 2018 10:19am
Checkmate's I-O combo reverses PD-1 resistance in melanoma
Apr 17, 2018 9:37am
Targeting a toll-like receptor could attack the root cause of lupus
Jan 26, 2018 3:25pm